1. Home
  2. Browse
  3. Hospital Practice
  4. Hematology & Oncology

Hematology & Oncology

16 - 30 of 32 Results
Sort Results:
Commentary: Changes to the REMS Requirements for Erythropoiesis-Stimulating Agents (ESA) June 2017
Article: Don't Use Obizur for Congenital Hemophilia A February 2015
Article: new warnings not to use high doses of IV ondansetron due to the risk of QT prolongation September 2012
Commentary: Zofran (Ondansetron) and QT Prolongation: An Update September 2012
Article: whether the various IV immunoglobulin G (IVIG) products can be substituted November 2011
Chart: Comparison of IVIG Products November 2011
Article: how to convert from epoetin to darbepoetin (Aranesp) December 2010
Commentary: Dose Conversions for Epoetin and Darbepoetin December 2010
Article: Provenge (sipuleucel-T), a new "therapeutic vaccine" to TREAT advanced prostate cancer June 2010
Article: new risk management program for erythropoiesis-stimulating agents...Aranesp, Procrit, and Epogen April 2010
Commentary: ESA APPRISE Oncology Program for Cancer Patients Using Procrit, Epogen, or Aranesp April 2010
Article: Ondansetron is being used more for acute nausea and vomiting January 2010
Article: Feraheme (ferumoxytol) will be promoted as an easier-to-use intravenous iron replacement September 2009
Commentary: “Off-Label” Uses of Ondansetron January 2008
Guideline: CDC Recommendations for Managing Acute Gastroenteritis Among Children (2003) January 2008